By Martin Mou 
 

CStone Pharmaceuticals' shares rose as much as 40% on Wednesday morning after the Chinese drug maker entered into a strategic collaboration with Pfizer Inc.

Pfizer will invest US$200 million to take a 9.9% stake in CStone, which will use the fresh capital to fund business expansion, CStone said Wednesday.

CStone has agreed to grant Pfizer an exclusive license to a monoclonal antibody in China, and the two companies will also join hands in developing and commercializing additional late-stage oncology therapies in Greater China, CStone said.

CStone shares were up 12% at HK$10.44 at midday.

 

Write to Martin Mou at martin.mou@wsj.com

 

(END) Dow Jones Newswires

September 30, 2020 00:35 ET (04:35 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Pfizer Charts.